Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Company Deals

Xbiome Strikes NewCo‑Style Technology Collaboration with Biogent Therapeutics for AI‑Driven Bispecific Antibody Development

Fineline Cube Aug 14, 2026
Company Deals

ACROBiosystems and Bailinke Pharmaceutical Form Strategic Partnership to Build AI‑Empowered Affinity Purification Solutions

Fineline Cube Aug 14, 2026
Company Deals

IASO Biotherapeutics Completes Acquisition of MediSix Therapeutics – Adding PEBL‑Based CAR‑T Cell Therapy Platform for T‑Cell Malignancies

Fineline Cube Aug 14, 2026
Company Deals

Hybio Pharmaceutical Grants Wansheng Pharmaceutical Exclusive China License for Semaglutide’s Glycemic Control Indication in Up-to-RMB 182.5 Million Deal

Fineline Cube Aug 13, 2026
Policy / Regulatory

NMPA Releases Draft Implementation Rules for the National Key R&D Program – Public Comment Open Through 12 Sept 2026

Fineline Cube Aug 14, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Fineline Cube Aug 17, 2026
Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Fineline Cube Aug 17, 2026
Company Drug

Zelgen’s ZG006 Receives Breakthrough Therapy Designation for Advanced Small Cell Lung Cancer

Fineline Cube Jul 11, 2025

China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that it has received breakthrough therapy...

Company Drug

Cosunter’s GST-HG131 Granted Breakthrough Therapy Designation for HBV Treatment in China

Fineline Cube Jul 11, 2025

China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced that it has received breakthrough therapy...

Company Drug

Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment

Fineline Cube Jul 11, 2025

China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that it has received conditional marketing approval...

Company Drug

Allist’s Furmonertinib Granted Priority Review for EGFR Exon 20 NSCLC in China

Fineline Cube Jul 11, 2025

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that its Category 1 small molecule...

Company Drug

HKYM Biopharma’s KM1 Receives NMPA Green-Light for Phase Ib/II Study in Advanced Solid Tumors

Fineline Cube Jul 11, 2025

Shenzhen-based oncolytic virus specialist HKYM Biopharma has announced receiving the green-light from the National Medical...

Company Drug

United Laboratories Receives FDA Approval for Clinical Study of UBT37034 in Overweight/Obesity Treatment

Fineline Cube Jul 11, 2025

Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that it has received...

Company Drug

CStone Pharmaceuticals Receives NMPA Approval for Local Production of Gavreto in China

Fineline Cube Jul 10, 2025

China-based CStone Pharmaceuticals (HKG: 2616) has announced that it has received approval from the National...

Company Deals

Biocytogen and BeOne Medicines Deepen Partnership with Global Antibody Licensing Agreement

Fineline Cube Jul 10, 2025

China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced a global antibody molecule licensing...

Company Drug

Eli Lilly’s Kisunla (Donanemab) Receives FDA Label Update with New Dosing Schedule for Alzheimer’s Treatment

Fineline Cube Jul 10, 2025

US pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has announced that the US Food...

Company Drug

Jiangsu Chia Tai Tianqing’s Culmerciclib Receives NMPA Review for Expanded Breast Cancer Indication

Fineline Cube Jul 10, 2025

Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...

Company Deals

Sironax Partners with Novartis on Brain Delivery Module Platform for CNS Drugs

Fineline Cube Jul 10, 2025

China-based biotech innovator Sironax has entered into a strategic agreement with Swiss pharmaceutical giant Novartis...

Company Deals

Novo Nordisk Invests $111 Million in Tianjin Quality Control Lab Expansion

Fineline Cube Jul 10, 2025

Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) has signed a Memorandum of Understanding (MOU)...

Company Drug

Simcere and Connect Biopharma’s Rademikibart NDA Accepted by China’s NMPA for Atopic Dermatitis

Fineline Cube Jul 10, 2025

The New Drug Application (NDA) for rademikibart, an anti-inflammatory monoclonal antibody (mAb) co-developed by China’s...

Company Deals

Anke Bio Secures Exclusive Rights to Bao Pharma’s Long-Acting FSH-CTP for China Market

Fineline Cube Jul 10, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced an exclusive distribution agreement with...

Company Deals Medical Device

ShuWen Biotech Completes RMB100 Million Series C1 Round to Advance Women’s Health Diagnostics

Fineline Cube Jul 10, 2025

Zhejiang-based ShuWen Biotech Co., Ltd announced the successful completion of an RMB100 million (USD 14...

Company Drug

IASO Biotherapeutics Receives Orphan Drug Designation in South Korea for Fucaso in Multiple Myeloma

Fineline Cube Jul 10, 2025

China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...

Company Deals

MSD to Acquire Verona Pharma for $10 Billion, Expanding Respiratory Portfolio

Fineline Cube Jul 10, 2025

In a landmark deal poised to reshape the respiratory disease treatment landscap US pharmaceutical giant...

Company Drug

Guangdong Taienkang Submits Marketing Application for Generic Vuity to China’s NMPA

Fineline Cube Jul 9, 2025

China-based Guangdong Taienkang Pharmaceutical Co., Ltd. (SHE: 301263) announced the submission of a marketing approval...

Company

Pascal Qian Appointed General Manager of BMS China Unit

Fineline Cube Jul 9, 2025

Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...

Company Deals

Adagene Collaborates with ConjugateBio to Develop Bispecific Antibody Drug Conjugates

Fineline Cube Jul 9, 2025

China-based Adagene Inc. (NASDAQ: ADAG) announced a strategic collaboration with US-headquartered biotech ConjugateBio Inc. to...

Posts pagination

1 … 172 173 174 … 709

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes
  • CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma
  • Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets
  • Shanghai Ark Biopharmaceutical Wins FDA Clearance for Ziresovir Phase II Trials in Severe Pediatric RSV
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clearance for Phase II Trial of HRS‑4729, a Triple‑Agonist Peptide Drug for Type 2 Diabetes

Company Drug

CanSino Biologics Files NDA in China for Td5cp, a First-In-Nation Adolescent and Adult DTaP Booster Vaccine

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑002, a Brain‑Penetrant BTK PROTAC for B‑Cell Non‑Hodgkin Lymphoma

Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.